Travere Therapeutics Future Growth
Future criteria checks 2/6
Travere Therapeutics is forecast to grow earnings and revenue by 62.3% and 24.5% per annum respectively. EPS is expected to grow by 65.2% per annum. Return on equity is forecast to be -617.3% in 3 years.
Key information
62.3%
Earnings growth rate
65.2%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 24.5% |
Future return on equity | -617.3% |
Analyst coverage | Good |
Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Oct 07Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
Aug 30Travere: Setback Presents Cautious Opportunity
Jul 18Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Jul 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 438 | -21 | -23 | -45 | 9 |
12/31/2025 | 302 | -164 | -101 | -148 | 13 |
12/31/2024 | 216 | -238 | -192 | -208 | 14 |
12/31/2023 | 145 | -376 | -322 | -280 | N/A |
9/30/2023 | 232 | -320 | -305 | -264 | N/A |
6/30/2023 | 223 | -315 | -288 | -245 | N/A |
3/31/2023 | 221 | -289 | -263 | -212 | N/A |
12/31/2022 | 109 | -331 | -215 | -186 | N/A |
9/30/2022 | 137 | -297 | -188 | -159 | N/A |
6/30/2022 | 178 | -249 | -114 | -87 | N/A |
3/31/2022 | 229 | -202 | -64 | -44 | N/A |
12/31/2021 | 132 | -217 | -39 | -15 | N/A |
9/30/2021 | 221 | -250 | -29 | -2 | N/A |
6/30/2021 | 204 | -237 | -56 | -27 | N/A |
3/31/2021 | 198 | -224 | -69 | -40 | N/A |
12/31/2020 | 198 | -169 | -67 | -43 | N/A |
9/30/2020 | 194 | -78 | -53 | -33 | N/A |
6/30/2020 | 187 | -92 | -71 | -54 | N/A |
3/31/2020 | 184 | -105 | -83 | -67 | N/A |
12/31/2019 | 175 | -146 | -74 | -58 | N/A |
9/30/2019 | 172 | -124 | -73 | -57 | N/A |
6/30/2019 | 169 | -142 | -62 | -47 | N/A |
3/31/2019 | 165 | -125 | -46 | -31 | N/A |
12/31/2018 | 164 | -103 | -45 | -25 | N/A |
9/30/2018 | 163 | -113 | -41 | -22 | N/A |
6/30/2018 | 162 | -76 | -31 | -12 | N/A |
3/31/2018 | 160 | -67 | -22 | -4 | N/A |
12/31/2017 | 155 | -60 | -7 | 7 | N/A |
9/30/2017 | 150 | -51 | N/A | 0 | N/A |
6/30/2017 | 144 | -70 | N/A | -2 | N/A |
3/31/2017 | 138 | -70 | N/A | -3 | N/A |
12/31/2016 | 134 | -48 | N/A | -3 | N/A |
9/30/2016 | 127 | -42 | N/A | 2 | N/A |
6/30/2016 | 121 | 101 | N/A | -2 | N/A |
3/31/2016 | 112 | 89 | N/A | 2 | N/A |
12/31/2015 | 100 | 117 | N/A | -1 | N/A |
9/30/2015 | 84 | 91 | N/A | -7 | N/A |
6/30/2015 | 64 | -33 | N/A | -23 | N/A |
3/31/2015 | 46 | 4 | N/A | -43 | N/A |
12/31/2014 | 28 | -111 | N/A | -46 | N/A |
9/30/2014 | 14 | -95 | N/A | -45 | N/A |
6/30/2014 | 6 | -89 | N/A | -32 | N/A |
3/31/2014 | 0 | -105 | N/A | -23 | N/A |
12/31/2013 | N/A | -35 | N/A | -18 | N/A |
9/30/2013 | N/A | -36 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TVTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TVTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TVTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TVTX's revenue (24.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: TVTX's revenue (24.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TVTX is forecast to be unprofitable in 3 years.